NASDAQ:SBPHSpring Bank Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spring Bank Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.63 +0.16 (+10.88 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$1.47Now: $1.63▼$1.6450-Day Range$1.40MA: $1.62▼$2.5752-Week Range$0.80Now: $1.63▼$4.80Volume202,025 shsAverage Volume231,886 shsMarket Capitalization$27.86 millionP/E RatioN/ADividend YieldN/ABeta1.27 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. It has a collaboration agreement with Gilead Sciences, Inc. for conducting a Phase II clinical trial examining the co-administration of inarigivir and Vemlidy in patients infected with chronic HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingSpring Bank Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.73, Spring Bank Pharmaceuticals has a potential upside of 6.3% from its current price of $1.63.Amount of Analyst CoverageSpring Bank Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesSpring Bank Pharmaceuticals has received 224 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSpring Bank Pharmaceuticals has received 280 “underperform” votes. (Add your “underperform” vote.)Community SentimentSpring Bank Pharmaceuticals has received 55.56% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote “Outperform” if you believe SBPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSpring Bank Pharmaceuticals does not currently pay a dividend.Dividend GrowthSpring Bank Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spring Bank Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.70% of the stock of Spring Bank Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.43% of the stock of Spring Bank Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Spring Bank Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spring Bank Pharmaceuticals is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spring Bank Pharmaceuticals is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpring Bank Pharmaceuticals has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.92 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SBPH Previous Symbol CUSIPN/A CIK1566373 Webwww.springbankpharm.com Phone508-473-5993Debt Debt-to-Equity Ratio0.10 Current Ratio2.07 Quick Ratio2.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book0.75Profitability EPS (Most Recent Fiscal Year)($1.47) Net Income$-24,100,000.00 Net MarginsN/A Return on Equity-70.32% Return on Assets-44.07%Miscellaneous Employees29 Outstanding Shares17,095,000Market Cap$27.86 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable $1.63 +0.16 (+10.88 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SBPH News and Ratings via Email Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter. Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions How has Spring Bank Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Spring Bank Pharmaceuticals' stock was trading at $1.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SBPH shares have increased by 40.5% and is now trading at $1.63. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Spring Bank Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Spring Bank Pharmaceuticals. When is Spring Bank Pharmaceuticals' next earnings date? Spring Bank Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Spring Bank Pharmaceuticals. How were Spring Bank Pharmaceuticals' earnings last quarter? Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.29. View Spring Bank Pharmaceuticals' earnings history. What price target have analysts set for SBPH? 4 brokers have issued 12-month target prices for Spring Bank Pharmaceuticals' stock. Their forecasts range from $1.50 to $2.00. On average, they expect Spring Bank Pharmaceuticals' share price to reach $1.73 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price. View analysts' price targets for Spring Bank Pharmaceuticals. Has Spring Bank Pharmaceuticals been receiving favorable news coverage? Headlines about SBPH stock have been trending somewhat negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Spring Bank Pharmaceuticals. Are investors shorting Spring Bank Pharmaceuticals? Spring Bank Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 29,500 shares, an increase of 21.4% from the December 31st total of 24,300 shares. Based on an average trading volume of 296,800 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are sold short. View Spring Bank Pharmaceuticals' Short Interest. Who are some of Spring Bank Pharmaceuticals' key competitors? Some companies that are related to Spring Bank Pharmaceuticals include Qualigen (QLGN), Zosano Pharma (ZSAN), Zynerba Pharmaceuticals (ZYNE), Leap Therapeutics (LPTX), Endonovo Therapeutics (ENDV), Aptorum Group (APM), Otonomy (OTIC), Antibe Therapeutics (ATBPF), Lipocine (LPCN), TapImmune (MRKR), Vaccinex (VCNX), Gemphire Therapeutics (GEMP), OncoSec Medical (ONCS), Galmed Pharmaceuticals (GLMD) and Aravive (ARAV). View all competitors. What other stocks do shareholders of Spring Bank Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), SCYNEXIS (SCYX), Associated British Foods (ABF), Apollo Global Management (APO), Chaarat Gold (CGH), Avadel Pharmaceuticals (AVDL) and China Unicom (Hong Kong) (CHU). Who are Spring Bank Pharmaceuticals' key executives? Spring Bank Pharmaceuticals' management team includes the following people: Mr. Martin J. Driscoll, Pres, CEO & Director (Age 60)Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 69)Dr. Nezam H. Afdhal, Chief Medical Officer (Age 62)Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 41)Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel. When did Spring Bank Pharmaceuticals IPO? (SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO. What is Spring Bank Pharmaceuticals' stock symbol? Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH." How do I buy shares of Spring Bank Pharmaceuticals? Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Spring Bank Pharmaceuticals' stock price today? One share of SBPH stock can currently be purchased for approximately $1.63. How big of a company is Spring Bank Pharmaceuticals? Spring Bank Pharmaceuticals has a market capitalization of $27.86 million. The company earns $-24,100,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe. What is Spring Bank Pharmaceuticals' official website? The official website for Spring Bank Pharmaceuticals is www.springbankpharm.com. How can I contact Spring Bank Pharmaceuticals? Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
